2017 Immuno-Oncology Symposium

Razvan Cristescum, Merck & Co. Inc, presenting Abstract #1, "Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab"

Orlando, FL - 2017 Clinical Immuno-Oncology Symposium - Razvan Cristescum, Merck & Co. Inc, presenting Abstract #1, "Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab," during Oral Abstract Session B at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium here today, Friday, February 24, 2017. The conference, which is a collaboration between the American Society of Clinical Oncology and Society for Immunotherapy of Cancer, is focused on clinical and translational research in immuno-oncology and the implications for clinical care. Photo by © ASCO/Luke Franke 2017